Navigation Links
PharmAthene Reports Year End 2008 Financial Results
Date:3/30/2009

following the Avecia acquisition, as well as increased travel expenses, non-cash stock compensation expense, and legal and consulting expenses.

For the year ended December 31, 2008, the Company's net loss attributable to common shareholders was $36.4 million or $1.59 per share, compared to net loss attributable to common shareholders of $17.7 million or $1.88 per share in the same period of 2007.

As of December 31, 2008, available cash, cash equivalents and short term investments totaled $22.9 million, excluding restricted cash totaling $13.3 million. In addition, on March 27, 2009, the Company closed on the public sale of an aggregate of 2,116,055 newly issued shares of its common stock at $2.60 per share and warrants to purchase an aggregate of 705,354 shares of its common stock at an exercise price of $3.00 per share, resulting in aggregate gross proceeds of approximately $5.5 million.

"The past year represented an important phase in the Company's growth cycle, during which time we successfully executed on our milestones with the goal of transitioning from a product development company to one emphasizing procurement and delivery of next-generation medical countermeasures to the Strategic National Stockpile," said David P. Wright, President and Chief Executive Officer of PharmAthene.

"Our acquisition of Avecia's biodefense vaccines portfolio, completed in April 2008, created an expanded product portfolio that now includes five potential best-in-class, next generation product candidates, and important critical mass - particularly with respect to our anthrax franchise," continued Mr. Wright.

"We anticipate achieving important milestones in 2009 in each of these programs. We expect our on-going Phase I clinical trial of Protexia(R) to be completed this year. In addition, we also expect to commence a Phase I clinical trial of Valortim(R) in combination with antibiotics. Notably, w
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PharmAthene to Present at the Rodman and Renshaw/Acumen BioFin 9th Annual Healthcare Conference
2. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... a famous wedding dress company offering many trendy designs. Today, ... Twitter, and Pinterest. The fans will have an opportunity to ... week. , Moreover, the company has extended its 2015 New ... for more information. , Angelweddingdress is a famous ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... Jan. 11 Welcome to Consumer,Reports Health ... Reports,and ConsumerReports.org cover issues pertaining to the ... (including natural medicines),mental health, diet and nutrition, ... fitness products, rates the effectiveness and affordability ...
... Fla., Jan. 11 Breckenridge,Pharmaceutical, Inc. announced ... Novartis concerning Trileptal(R) and that the U.S. ... Drug,Application for oxcarbazepine 150mg, 300mg and 600 ... Breckenridge enjoys a shared 180-day exclusivity ...
... caused by type 2 diabetes will more than double ... major causes falls, according to new research by The,University ... published in the January 7 edition of the Medical ... and injury in Australia from 1993 to 2023,measuring the ...
... study finds cholesterol-lowering drugs reduce risk of major vascular events ... with diabetes should be considered for treatment with cholesterol-lowering statins. ... in the Jan. 12 issue of The Lancet . ... the risk of major vascular events in a wide range ...
... Fla., Jan. 11 Life Brokerage Partners,announces ... National,Life Group and Nationwide. With these new ... to products at some of the most,exclusive ... as a,national insurance brokerage agency., New ...
... Jan. 11 /Xinhua-PRNewswire/ -- Sundia MediTech,(Shanghai) Company recently announced ... Dr. Joseph Zhu and Dr. Shu Gao. Dr. Zhu ... Dr. Gao as the Vice,President in charge of Chemical ... Zhu got his college,education in chemistry in Nanjing University ...
Cached Medicine News:Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:UQ research predicts type 2 diabetes explosion 2Health News:Statin Therapy Helps Diabetic Patients 2Health News:Life Brokerage Partners Adds New Insurance Carriers 2Health News:CRO Company Sundia Welcomes New Members to Its Executive Team 2
(Date:1/23/2015)... More than a third of reproductive-aged women enrolled in ... insurance, filled a prescription for an opioid pain medication each ... Morbidity and Mortality Weekly Report (MMWR). Opioids ... to severe pain.  They are also found in some prescription ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... from Cytel join peers in examining the rise of ... ... CAMBRIDGE, Mass., June 23 Cytel,s renowned adaptive,trial design and implementation ... will lead workshops and case,study reviews at the Annual Meeting of ...
... 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) ... Annual Scientific Meeting of,the American Headache Society, which ... Boston, MA. The oral platform abstract presentation,"Inhaled Loxapine, ...
Cached Medicine Technology:Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting 2Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
... Spaced, Expandable, Multichannel Pipettor The ... boosts productivity with an industry breakthroughequal tip ... of a slide rod. This innovation allows ... between vessels with different configurations. Adjustable ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
Medicine Products: